regulated within the time frame of hours to days. For example, in diabetes mellitus and fasting, the heart can switch to almost exclusively using fatty acids for its ATP requirements. This occurs due both to acute changes in allosteric and phosphorylation control of enzymes involved in glucose and fatty acid metabolism as well as chronic alterations in the expression of metabolic enzymes. In diabetes and fasting, changes at the gene regulatory level usually occur in response to constraints on cardiac ATP production (2, 6, 18, 32) . This includes changes in enzymes involved in fatty acid oxidation pathways, which occurs, in part, through the nuclear receptor peroxisome proliferator activated receptor (PPAR)-␣.
PPAR-␣ is a ligand-activated transcription factor activated by the binding of long-chain fatty acids and related compounds (9, 15) . PPAR-␣ dimerizes with the retinoid X receptor and binds peroxisome proliferator response elements in the promoter region of specific genes (6, 9, 11) . This binding recruits transcriptional machinery to the promoter and increases gene transcription (9) . PPAR-␣ alters the transcription of several enzymes involved in fatty acid oxidation including carnitine palmitoyl transferase (CPT)-1, fatty acid synthase, and 3-ketoacyl-CoA thiolase (2, 6, 18, 32) . The PPAR-␣ ligand WY-14,643 is one effective approach to increase the expression of PPAR-␣-controlled genes involved in fatty acid oxidation.
PPAR-␣ has also been shown to regulate enzymes involved in glucose metabolism (24, 28, 29) . Metabolism of glucose in the cardiac myocyte occurs in two stages: 1) glycolysis converts glucose to pyruvate in the cytosol and 2) glucose oxidation encompasses the metabolism of mitochondrial pyruvate to acetyl CoA and entry into the citric acid cycle (21) . The rate of glucose oxidation is dependent on flux through the pyruvate dehydrogenase complex (PDC), a mitochondrial enzyme complex, which converts pyruvate to acetyl CoA (21) . Phosphorylation of PDC by the associated enzyme pyruvate dehydrogenase kinase (PDK) inactivates the PDC complex (12, 25-27, 29, 30) , whereas pyruvate dehydrogenase phosphatase dephosphorylates and reactivates the enzyme (for reviews, see Refs. 16, 19, and 21) .
As well as its regulation by reversible phosphorylation, PDC is regulated acutely through negative feedback by acetyl CoA and NADH, which are end-products of both the PDC reaction itself and mitochondrial fatty acid oxidation (22) . Acetyl CoA and NADH accumulation also activates PDK, which phosphorylates and inhibits PDC, thereby decreasing glucose oxidation (21) . As well, increased pyruvate supply can inhibit PDK, thereby stimulating PDC, a process that may occur in isolated hearts perfused with insulin (14, 20) .
There are currently four known isoforms of PDK (PDK1, PDK2, PDK3, and PDK4), of which PDK1, -2, and -4 are present in the heart (5). Recent studies have shown that stimulation of PPAR-␣ can increase PDK expression in some tissues (24, 28, 29) . This provides a potential mechanism by which a PPAR-␣-dependent increase in fatty acid oxidation is accompanied by a downregulation of glucose oxidation. Wu et al. were the first to show that fasting and diabetes increase the cardiac (30) and skeletal muscle expression of PDK through a PPAR-␣-dependent mechanism (28) . Both fasting and treatment with the PPAR-␣ activator WY-14,643 have been reported to cause an increase in cardiac and renal PDK4 in wild-type mice but not in PPAR-␣ knockout mice (29) . The relative importance of either 1) PPAR-␣-induced changes in PDK expression or 2) allosteric control of PDC in regulating glucose oxidation in the heart has not been determined.
Because PPAR-␣ activation also directly increases fatty acid oxidation, PPAR-␣ has the potential to regulate glucose oxidation at three levels: 1) allosteric feedback at the level of PDC by fatty acid-derived acetyl CoA and NADH, 2) allosteric activation of PDK and inhibition of PDC by these fatty acid metabolites, and 3) increased expression of PDK.
Mice with cardiac-restricted overexpression of PPAR-␣ (MHC-PPAR-␣ mice) exhibit many characteristics of diabetic cardiomyopathy, including increases in CPT-1 mRNA, acyl CoA oxidase, uncoupling protein 2, and PDK4 (10) . In the present study, we used MHC-PPAR-␣ mice to analyze the impact of PPAR-␣ overexpression on cardiac fuel selection and the response of cardiac glucose oxidation to fasting in relationship to cardiac PDC activity and PDK protein expression. We also determined whether PPAR-␣ controls glucose oxidation in the heart primarily by regulating PDK expression or through its effects on fatty acid oxidation.
MATERIALS AND METHODS
Animals. MHC-PPAR-␣ mice (of the 402-2 line) were produced as previously described (10) , and wild-type littermates were used as controls. In the second portion of the study, animals were either fasted for 48 h or provided with 0.1% (wt/wt) WY-14,643 in standard rodent chow ad libitum for 1 wk. Male animals (age 12 wk) were used in both wild-type and PPAR-␣ transgenic groups. The University of Alberta adheres to the principles for biomedical research involving animals developed by the Council for International Organizations of Medical Sciences and complies with National Institutes of Health animal care guidelines.
Isolated working heart model. Hearts were perfused as described by Belke et al. (4) . Briefly, hearts were aerobically perfused in a retrograde fashion using an 18-gauge needle at a preload of 7 mmHg and an aortic afterload of 50 mmHg for 30 min with Krebs-Henseleit solution containing 0.4 mM palmitate, 3% BSA, 5 mM glucose, 2.5 mM calcium, and 100 U/ml insulin. The perfusate was oxygenated with 95% O 2-5% CO2, and coronary flows were measured using a transonic flow probe system. Heart function was measured using an in-line pressure transducer, and data collection was performed using a BIOPAC data-acquisition system. Specifically, cardiac function was monitored in isolated working hearts using a pressure transducer in the aortic outflow line as well as flow probes in the left atrial inflow lines and aortic outflow line. This technique determines aortic diastolic pressure of the heart. Fatty acid oxidation and glucose oxidation rates were measured as previously described by Saddik and Lopaschuk (23 [9,10- 3 H]palmitate. Glycolytic flux was measured as previously described (4) by measuring the amount of 3 H2O released from the metabolism of [5-3 H]glucose by the triosephosphate isomerase and enolase steps of the glycolytic pathway (23) .
PDC activity measurements. PDC activities were measured using a revised protocol based on the radiometric assay described by Constantin-Teodosiu et al. (8) . Briefly, for measurement of active PDC, frozen mouse heart tissue was homogenized in buffer containing 200 mM sucrose, 50 mM KCl, 5 mM EGTA, 50 mM Tris ⅐ HCl, 50 mM NaF, 50 mM sodium pyrophosphate (NaPPi), 5 mM dicholoroacetate, and 0.1% Triton X-100 (pH 7.8). For assay of "total" PDC activity (dephosphorylated), frozen tissue was homogenized in buffer containing 1 mM CaCl2 but in the absence of NaF, NaPPi, and EGTA. The total PDC samples were incubated in 0.8 mM MgCl2 at 37°C for 20 min. Both active and total samples were then incubated in assay buffer (150 mM Tris ⅐ HCl, 0.75 mM EDTA, 0.75 mM nicotinamide adenine dinucleotide, 1.5 mM thiamine pyrophosphate, 5 mM EGTA, 5 mM dichloroacetate, and 0.75 mM CoA), and the reaction was initiated by the addition of pyruvate. The reaction was terminated by perchloric acid. Samples were neutralized and centrifuged, and the resulting supernatant was used to determine acetylCoA content. Acetyl CoA was converted to [ 14 C]citrate and separated from unreacted radioactivity using Dowex resin (50WX8, 100-200 mesh). The amount of acetyl CoA was determined by comparison of acetyl CoA standard curves run in parallel in each experiment.
Immunoblotting. Samples were prepared as previously described by Holness et al. (13) . Cardiac samples were homogenized in ice-cold buffer containing 10 mM Tris ⅐ HCl, 150 mM NaCl, 1% Igepal, 0.4% sodium deoxycholate, 0.1% SDS, 45 mM sodium orthovanadate, 0.2 mM PMSF, 10 g/ml leupeptin, 1.5 mg/ml benzamidine, 50 g/ml aprotinin, and 50 g/ml pepstatin A (in DMSO), pH 8.0. Samples (25 g total protein) were subjected to SDS-PAGE and subsequently transferred electrophoretically to nitrocellulose membranes. Membranes were blocked with Tris-buffered saline supplemented with 0.05% Tween (buffer A) and 5% (wt/vol) nonfat powdered milk. The nitrocellulose blots were incubated overnight with polyclonal antisera raised against specific recombinant PDK isoforms, washed in buffer A (3 ϫ 10 min), and incubated with the horseradish peroxidase-linked IgG anti-rabbit secondary antibody [1:5,000 dilution in 1% (wt/vol) nonfat milk in buffer A]. Bound antibody was visualized using enhanced chemiluminsence according to the manufacturer's instructions. The blots were exposed to Hyperfilm, and signals were quantified by scanning densitometry and analyzed with Molecular Analyst software (Bio-Rad).
Statistics. Values are expressed as means Ϯ SE. Student's unpaired t-test was used to evaluate significance between two groups; however, groups with unequal standard deviations were evaluated using the nonparametric alternate Welch t-test. A value of P Ͻ 0.05 was determined to be significant.
RESULTS
Contractile function. The contractile function of isolated perfused working hearts from ad libitum-fed MHC-PPAR-␣ mice and control animals perfused with 5 mM glucose, 0.4 mM palmitate, and 100 U/ml insulin is shown in Table 1 . There were no differences in heart rate, peak systolic pressure, coronary flow, cardiac output, or cardiac work in MHC-PPAR-␣ mice and their respective controls over the 30-min aerobic perfusion period. Therefore, metabolic measurements in these hearts were not confounded by differences in metabolic demand. Although heart rates in the isolated hearts were lower than rates seen in vivo, cardiac function in these hearts was comparable to isolated working heart function observed in other published studies (1, 3) , and function was maintained throughout the entire perfusion period.
Metabolism and PDC activity measurements. The 402-2 line of PPAR-␣ transgenic mice graciously provided by Dr. Daniel P. Kelly exhibit cardiac-restricted transgene expression that is ϳ80-fold higher that that of wild-type littermates (10) . In the present study, MHC-PPAR-␣ hearts exposed to 0.4 mM palmitate had significantly higher palmitate oxidation rates than the rates measured from hearts of wild-type animals (Fig.  1A) . This increase in palmitate oxidation rates was paralleled by a significant decrease in glucose oxidation rates of MHC-PPAR-␣ mice compared with wildtype animals (Fig. 1B) . The relative contribution of palmitate and glucose to the production of acetyl CoA is shown in Fig. 1C , indicating that MHC-PPAR-␣ mice derive more acetyl CoA from palmitate oxidation compared with control animals (71.5% vs. 47.2%, respectively). However, despite this decrease in glucose oxidation pyruvate dehydrogenase in the active form measured in heart extracts from MHC-PPAR-␣ mice was not different than wild-type animals (Fig. 1D) . Total PDC activity was also similar in both animal groups (Fig. 1D) . Interestingly, we also found that cardiac PDC activity of mice lacking the PPAR-␣ gene was 2,391 Ϯ 651 nmol ⅐ g dry weight Ϫ1 ⅐ min Ϫ1 , which was not different from MHC-PPAR-␣ mice (Fig. 1D ) even though previous studies have shown that glucose oxidation rates are significantly increased in animals lacking PPAR-␣ (7).
Expression levels of PDK and PDH E 1 -␣. To determine whether the low glucose oxidation rates of the PPAR-␣ transgenic mice are due to increases in the expression of PDK, Western blot analysis was performed for all three PDK isoforms present in the heart (PDK1, -2, and -4). Cardiac expression levels of PDK1 were significantly increased in MHC-PPAR-␣ mice, whereas levels of PDK2 and -4 remained unchanged (Fig. 2, A-C) . Therefore, contrary to our expectations, protein expression of PDK4 was only marginally influenced by PPAR-␣ overexpression. We also measured the expression of PDH E 1 -␣ (the subunit of PDC that is phosphorylated by PDK) in wild-type and MHC-PPAR-␣ mouse hearts (Fig. 2D) . Similar to the PDK isoforms, no difference in PDH E1-␣ was observed between wild-type and MHC-PPAR-␣ mouse hearts.
Metabolism and PDC activity measurements of treated animals. In an attempt to amplify differences among the groups in terms of PDC activity, wild-type and MHC-PPAR-␣ mice were also treated with the PPAR-␣ agonist WY-14,643 for 1 wk or fasted for 48 h before study. There were no differences between the preperfusion body weights of fed and fasted wild-type animals and only a minor drop in the preperfusion weight (ϳ10%) of the fasted MHC-PPAR-␣ mice compared with their fed counterparts (data not shown). However, weights before fasting were not recorded, and thus the weight loss and level of starvation observed in each group may be underestimated.
Treatment with WY-14,643 resulted in significantly lower glucose oxidation rates in MHC-PPAR-␣ mouse hearts than in wild-type animals (Fig. 3A) . Fasting of animals for 48 h resulted in a severe drop in cardiac glucose oxidation rates in both animal group (Fig. 3B ), although no difference was observed between control and MHC-PPAR-␣ mice. Even with these drastic changes in glucose oxidation rates, no change in PDC activity occurred with WY-14,643 treatment (Fig. 3C) or fasting (Fig. 3D) . These data suggest that the rates of glucose oxidation are not closely correlated with rates of PDC activity. However, fasting of wild-type animals, a condition known to increase PDK expression (30), did cause a decrease in PDC in the active Values are means Ϯ SE; n ϭ 4 control (wild type) and 7 overexpressing peroxisome proliferator-activated receptor-␣ (MHC-PPAR-␣) mouse hearts. Hearts were perfused at 7 mmHg of left atrial preload and 50 mmHg of aortic after load, as described in MATERIALS AND METHODS.
form compared with the fed wild-type animals (2,386 Ϯ 706 vs. 4,268 Ϯ 852 nmol ⅐ g dry weight Ϫ1 ⅐ min Ϫ1 for fasted and fed animals, respectively). This result confirms previous studies that show fasting can alter PDC activity. However, these changes in PDC can be dissociated from changes in glucose oxidation.
To determine whether the pyruvate supply from glycolysis was responsible for altering glucose oxidation rates in fasted hearts, we measured glycolytic flux in these animals. Glycolytic rates after 30-min aerobic perfusion were 5,267 Ϯ 1,110 and 5,129 Ϯ 489 nmol [ 3 H]glucose ⅐ g dry wt Ϫ1 ⅐ min Ϫ1 in fasted wild-type and PPAR-␣ transgenic mouse hearts, respectively. There was no correlation between PDC activity and rates of glucose oxidation in hearts perfused under our conditions (R ϭ 0.181, r 2 ϭ 0.033). Similarly, palmitate oxidation and PDC activity had no correlation in these perfused hearts (R ϭ 0.022, r 2 ϭ 0.000).
DISCUSSION
Under resting conditions in vivo, the mouse heart derives ϳ40-60% of its energy from the oxidation of fatty acids, whereas the remainder originates primarily from glycolysis and glucose oxidation (23) . However, the relative contribution of fatty acid oxidation to energy production increases in fasting and diabetes. It has been recently reported that the cardiac metabolic phenotype induced by PPAR-␣ overexpression, in particular enhanced expression of genes involved in myocardial fatty acid utilization and evidence of altered lipid balance, mimics that found in uncontrolled or poorly controlled diabetes (10) . Perfusion of mouse hearts with a cardiac-specific overexpression of PPAR-␣ allows analysis of perturbations of metabolic fuel handling that is retained ex vivo under controlled conditions of substrate delivery. Data from other laboratories have clearly shown that PPAR-␣ activation (28) and overexpression (10) causes an increase in PDK4 expression, suggesting a direct role of PPAR-␣ in controlling glucose oxidation. However, although we show that mice overexpressing the PPAR-␣ gene have significantly decreased glucose oxidation rates (10), we found that PDC activity was not different between wild-type and MHC-PPAR-␣ mice under a variety of conditions in which the glucose oxidation rates were varied. In a previous study (7) , hearts from PPAR-␣ knockout mice showed a decrease in fatty acid oxidation and an increase in glucose oxidation, the opposite metabolic phenotype of the MHC-PPAR-␣ mice. These dramatic changes in glucose oxidation were also not evidenced by changes in PDC activity, as the PPAR-␣ knockout mice and the MHC-PPAR-␣ animals exhibited similar PDC activities (data not shown). This suggests that PPAR-␣ does not alter glucose oxidation at the level of PDK or PDC, but most likely is acting secondary to changes in fatty acid oxidation.
The PDC assay utilizes excess pyruvate to form acetyl CoA, and careful procedures prevent the phosphorylated state of PDC from being altered during the experiment. In this manner, the PDC assay reflects the amount of PDC in the phosphorylated state but not the physiological PDC flux. A second determinant of flux through PDC is the concentration of substrates and products of the reaction (22) . Increasing levels of acetyl CoA and NADH will feedback and inhibit the PDC complex in two ways: 1) by activation of PDK (21), O) ., tricarboxylic acid cycle (TCA) production, and pyruvate dehydrogenase enzyme complex (PDC) activity of isolated working hearts from wild-type and peroxisome proliferator-activated receptor (PPAR)-␣-overexpressing (MHC-PPAR-␣) mice. Steady-state rates of palmitate oxidation (A) and glucose oxidation (B) were measured as described in MATERIALS AND METHODS. TCA cycle acetyl CoA production (C) was calculated from the palmitate and glucose oxidation rates, using a value of 8 mol of acetyl CoA per 1 mol of palmitate oxidized and 2 mol of acetyl CoA per 1 mol of glucose oxidized. PDC activity was measured in the "active" form (PDCa) and in the dephosphorylated "total" form (PDCt) (D). Values are means Ϯ SE of 5 control hearts and 7 MHC-PPAR-␣ hearts for palmitate oxidation, glucose oxidation, and TCA cycle activity and 5 control hearts and 8 MHC-PPAR-␣ hearts for PDC activity. * Significantly different from control hearts, P Ͻ 0.05. which is likely not the mechanism active in these hearts as evidenced by our measurements of PDC activity; and 2) acetyl CoA and NADH can inhibit the PDC complex directly to decrease the flux through the complex (22) . This action is through negative feedback regulation, where fatty acid oxidation can inhibit glucose oxidation at the level of PDC. We were unable to measure the changes due to negative feedback as our in vitro assay cannot reflect limiting substrate or product levels within the mitochondrial matrix. However, our data suggest that the main determinant of flux through PDC of these hearts is the substrate/product concentration, as we observed no changes in PDC activity in the unphosphorylated form. In this study, we used a physiological level of palmitate (0.4 mM) to measure negative feedback of the PDC enzyme complex. Future studies using a higher concentration of palmitate may provide further insight into the PPAR-␣ regulation of glucose oxidation through feedback inhibition of PDC.
It is possible that the expressional level of PDK4 was not high enough in the MHC-PPAR-␣ mouse hearts to reflect a change in the active form of PDC. Previous studies (10) have shown a larger increase in PDK4 than we observed in our study. However, Wu et al. (28) demonstrated an increase in PDK4 expression with both starvation and treatment with WY-14,643. Therefore, to amplify these changes, we treated animals with WY-14,643 or by fasting. Under these conditions, PDK expression should have been sufficient to cause changes in the phosphorylated state of the PDC complex. In wild-type hearts, we did observe a decrease in PDC activity in both fasted and WY-14,643-treated mice. This indicates an increase in phosphorylated PDC and suggests PDK involvement. These data also support previous studies that demonstrated that the levels of PDK are indeed altered during both fasting and treatment with WY-14,643. However, we were unable to demonstrate any changes in PDC activity in the fed, fasted, or WY-14,643-treated MHC-PPAR-␣ mice compared with wild-type controls. Taken together, the data can be interpreted to show that PDK expression in the MHC-PPAR-␣ mice (regardless of treatment) is not the main determinant of the decreased flux through pyruvate dehydrogenase. In addition to feedback inhibition, diminished pyruvate supply may also play a role in the decreased glucose oxidation rates observed in hearts from the MHC-PPAR-␣ mice. Expression of both glucose transporter GLUT4 and phosphofructokinase is decreased in MHC-PPAR-␣ mice compared with controls (10). This reduction in pyruvate supply from glucose uptake and glycolysis would contribute to the reduced glucose oxidation rates in the heart. Reduced pyruvate levels in vivo may feed forward to inhibit flux through the PDC complex. This inhibition by decreased pyruvate supply would not be detected in our in vitro assay. However, our measurements of glycolytic flux in fasted wild-type and PPAR-␣ transgenic animals suggest that pyruvate supply is not limiting in these hearts.
A previous study (31) has suggested that PPAR-␣ expression is reduced under conditions where fatty acid utilization is high, and thus providing the synthetic PPAR-␣ activator WY-14,643 can further activate PPAR-␣. Treatment with WY-14,643 would ensure complete activation of the PPAR-␣ protein; however, it has not been proven that pharmacological treatment by WY-14,643 is required to observe changes in metabolism in these transgenic mice. A diet of WY-14,643 for 7 days has been shown to moderately activate PPAR-␣ (17) . With the use of a similar protocol, we found that mean steady-state rates of palmitate oxidation were significantly increased in hearts of MHC-PPAR-␣ animals administered WY-14,643 compared with MHC-PPAR-␣ animals maintained on standard high-carbohydrate/low-fat diet. By contrast, dietary WY-14,643 administration did not increase exogenous palmitate oxidation rates in perfused hearts from wild-type mice. The latter findings suggest that PPAR-␣ may be saturated with its physiological ligand in fed wild-type mice, whereas the PPAR-␣ ligand may be limiting for full activation of fatty acid oxidation in fed MHC-PPAR-␣ mice. Overall, our data suggest that PPAR-␣ activity may be relatively suppressed in the fed state, such that myocardial fatty acid oxidation increases with increased PPAR-␣ expression levels. However, ligand activation by fatty acids may become limiting when the expression level of PPAR-␣ is increased by overexpression.
An alternative explanation for the discrepancy between PDK expression and glucose oxidation in MHC-PPAR-␣ and control mice is that differences in expression or activity of the intrinsically linked PDH phosphatase may compensate for the increased PDK expression in hearts from MHC-PPAR-␣ mice. Thus the net phosphorylated state of the PDC complex would not be altered, and the feedback inhibition would be the main determinant of flux in these hearts. Whether the phosphatase is increased in a compensatory mechanism in these transgenic mice to maintain total energy production is not clear. Further studies are required to determine the role, if any, of the phosphatase. However, alterations in PDH phosphorylation would be expected to alter the ratio of PDH active to PDH total in these hearts, which did not occur.
In conclusion, we suggest that flux through the PDC complex in MHC-PPAR-␣ hearts is dependent mainly on the substrates and products of the reaction rather than by altered PDC phosphorylation by PDK. Although the exact mechanism remains to be determined, we have demonstrated that there is a disconnect between PDC phosphorylation and glucose oxidation rates such that PDC phosphorylation cannot be equated directly to glucose oxidation rates in the heart. 
